Reactive oxygen species (ROS) and serum ferritin levels are both considered to be important biological factors in the pathogenesis of myelodysplastic syndrome (MDS). This study evaluated the levels of ROS in 40 patients with MDS (19 males and 21 females) using the Free Radical Analytical System, FRAS4, and derivatives of reactive oxygen metabolite kits. The patients' mean age was 67.3 years (range 58 -86 years). The sera of 34 (85%) patients exhibited higher levels of oxidative stress than the reference range. There was a positive correlation between ROS levels and serum ferritin levels, and a negative correlation between ROS levels and haemoglobin levels. There was a negative relationship between serum haemoglobin and ferritin levels. The results indicated that iron accumulation or severe anaemia could contribute to oxidative stress in MDS patients. Iron chelation and antioxidant therapy may be suitable for the management of MDS.
Introduction
Inflammatory cytokines, such as tumour necrosis factor-α (TNF-α), 1 and oxidative stress are implicated as pathogenetic factors for myelodysplastic syndrome (MDS) 2 -5 and the progression of leukaemia. 6 A possible association between oxidative stress and karyotypical abnormalities in MDS has also been reported. 7 In addition to a decrease in the reduced form of glutathione, an increase in the production of reactive oxygen species (ROS) in the red blood cells and platelets of patients with MDS has been reported. 8 One of the aetiological agents leading to the increased ROS production in these patients is the over-accumulation of iron molecules; iron accumulation is mediated by both red blood cell transfusion and a decrease in the levels of hepcidin, which causes hyperabsorption of iron. 4,9
Patients and methods

STUDY POPULATION
Patients with MDS were recruited from the five collaborating hospitals between January 2009 and September 2010. The clinical characteristics of these patients were recorded as refractory anaemia with or without multilineage dysplasia, refractory anaemia with excess blasts I (RAEB-I), and refractory anaemia with excess blasts II (RAEB-II). 10 Patients treated with cytotoxic drugs and transfusion-dependent cases were excluded from the study.
The study was approved by the Ethical Committee of Himeji Dokkyo University (Himeji, Hyogo, Japan), and written informed consent was obtained from all participants.
SAMPLE COLLECTION AND STUDY ASSESSMENTS
Blood samples were collected, without the use of an anticoagulant, immediately after enrolment in the study, and serum was separated and stored at -80°C until analysis. The serum oxidative stress level was evaluated by measuring ROS using derivatives of Reactive Oxygen Metabolite (dROM) Tests (Wismerll Co. Ltd, Tokyo, Japan) and the Free Radical Analytical System, FRAS4 (Wismerll Co. Ltd, Parma, Italy) as described previously. 11, 12 Briefly, serum samples were diluted in an acidic buffer (pH 4), which resulted in the production of free ferrous and ferric ions. These ions produce alkoxy and peroxy radicals from hydrogen peroxide, in accordance with Fenton's reaction, after which the radicals oxidize an alkylsubstituted aromatic amine in a chromogenic mixture, which transforms them into pink-coloured derivatives. The FRAS4 was used to measure the colourization quantitatively, and the results were expressed in conventional arbitrary units, (Carr U) where 1 Carr U is equal to 0.08 mg/dl hydrogen peroxide. Reference values provided by the manufacturer ranged from 200 to 300 Carr U. Whole blood haemoglobin levels were measured using an automatic haematology analyser, XE-2100 (Sysmex Corp., Kobe, Japan). Serum ferritin levels were determined by means of a fully-automated chemiluminescent enzyme immunoassay system, Lumipulse ® series (Fujirebio, Tokyo, Japan), according to the manufacturer's instructions.
STATISTICAL ANALYSES
Statistical analyses were performed with the StatView™ statistical package, version 5.0 (SAS Institute Inc., San Jose, CA, USA). Correlation analysis employed the Fisher's Z transformation. A P-value < 0.05 was considered to be statistically significant.
Results
In total, 40 patients with MDS (19 males, 21 females) were included in the study: 35 were outpatients and five were inpatients. The mean (range) age of the MDS patients was 67.3 (58 -86) years. Five patients had refractory anaemia, 32 had refractory anaemia with multilineage dysplasia, one had RAEB-I and two had RAEB-II.
The results of the evaluation of serum oxidative stress levels are shown in Fig. 1 . The sera of 34 (85%) patients exhibited higher dROM values than the reference range. There was a positive correlation between dROM levels and serum ferritin levels ( Fig. 1A ; P = 0.0117), and a negative correlation between dROM levels and serum K Saigo, M Takenokuchi, Y Hiramatsu et al. Ferritinaemia and severe anaemia contribute to oxidative stress in MDS haemoglobin levels ( Fig. 1B ; P = 0.0134). A significant negative correlation was also observed between serum haemoglobin and ferritin levels ( Fig. 1C ; P = 0.0004).
Discussion
The present study demonstrated that both ferritinaemia and anaemia affect the redox state of MDS patients. High ferritin or overaccumulation of iron is a well-known factor contributing to increased oxidative stress through the Fenton reaction and by other mechanisms. 13 At the same time, anaemia itself is related to oxidative stress, even in iron-deficient patients. 11 Moreover, according to Choi et al., 14 hypoxia induced by severe anaemia is directly related to reduced hepcidin production, a key negative regulator of iron absorption and release from macrophages. 15 They maintained that anaemia-induced ROS, and ROS-induced inappropriate expression of the CCAAT/enhancer-binding protein alpha (C/EBPα) and signal transducer and activator of transcription 3 (STAT-3) genes and DNA binding are implicated in this phenomenon. 14 Recently, Ghoti et al. 16 reported increased hepcidin levels during iron chelation treatment with deferasirox. Another possible cause of high oxidative stress in MDS patients might be high cytokinaemia, due mainly to TNF-α, which is known as a producer of oxygen radicals. 17, 18 The present study and those mentioned above suggest the potential usefulness of antioxidant therapy for MDS patients. In fact, partial effectiveness of ascorbic acid 19 or amifostine, a thiol antioxidant, 20 has been reported for MDS. It has also been reported that iron chelators can act as antioxidants, 21 and some patients have exhibited haematopoietic recovery from transfusion dependency with iron-chelating agents. 22 Moreover, agents that inhibit nuclear factor κB, including curcumin and resveratrol, are expected to have anticancer and antioxidant properties. 23 The present study and previously published reports 19 -23 seem to suggest a possible role for antioxidant therapy in the management of patients with MDS.
